

Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

U-2932

RRID:CVCL_1896

Type: Cell Line

Proper Citation

Ubigen Cat# YC-C059, RRID:CVCL_1896

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1896

Proper Citation: Ubigen Cat# YC-C059, RRID:CVCL_1896

Description: Cell line U-2932 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse large B-cell lymphoma activated B-cell type

Defining Citation: [PMID:12533045](#), [PMID:20054396](#), [PMID:23257783](#), [PMID:23292937](#), [PMID:23295736](#), [PMID:25485619](#), [PMID:25894527](#), [PMID:26589293](#), [PMID:27566572](#), [PMID:28196595](#), [PMID:29416618](#), [PMID:29533902](#), [PMID:29666304](#), [PMID:30165192](#), [PMID:31160637](#)

Comments: Donor information: Originally the patient was suffering from Hodgkin lymphoma., Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572)., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: U-2932

Synonyms: U2932

Cross References: EFO:EFO_0006499, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-4527, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03473452, cancercellines:CVCL_1896, ChEMBL-Cells:ChEMBL4295421, ChEMBL-Targets:ChEMBL4296507, Cosmic:1487546, Cosmic:1517654, Cosmic:1945196, DSMZ:ACC-633, DSMZCellDive:ACC-633,

EGA:EGAS00001000610, GEO:GSM1035339, GEO:GSM1059802, GEO:GSM1374971, PharmacDB:U2932_1621_2019, PRIDE:PXD000589, Progenetix:CVCL_1896, PubChem_Cell_line:CVCL_1896, Ubigene:YC-C059, Wikidata:Q54973560

ID: CVCL_1896

Vendor: Ubigene

Catalog Number: YC-C059

Record Creation Time: 20250130T072907+0000

Record Last Update: 20260904T020959+0000

Ratings and Alerts

No rating or validation information has been found for U-2932.

No alerts have been found for U-2932.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Demel UM, et al. (2026) Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(17), e11449.

Zhao J, et al. (2026) Construction and experimental verification of a prognostic model based on tumor-infiltrating lymphocytes related genes (TILRGs) in diffuse large B-cell lymphoma. SLAS technology, 39, 100425.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Duranti C, et al. (2025) Antineoplastic Activity of a Novel Trispecific Single-Chain Antibody Targeting the hERG1/??1 Integrin Complex and TRAIL Receptors. Molecular cancer therapeutics, 24(10), 1584.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood

cancer discovery, 6(6), 580.

Shi X, et al. (2025) NFS1, together with FXN, protects cells from ferroptosis and DNA damage in diffuse large B-cell lymphoma. Redox biology, 87, 103878.

McCrury M, et al. (2024) Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Molecular cancer therapeutics, 23(3), 316.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Mehdi SH, et al. (2024) Development of New Diffuse Large B Cell Lymphoma Mouse Models. Cancers, 16(17).

Pieper NM, et al. (2024) Inhibition of bromodomain and extra-terminal proteins targets constitutively active NF κ B and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell communication and signaling : CCS, 22(1), 415.

Eken JA, et al. (2024) Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. The Journal of experimental medicine, 221(5).

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

Zeng H, et al. (2023) Exosomal PD α L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B α cell lymphoma. Oncology reports, 49(5).

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer discovery, 13(1), 216.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. Cancer discovery, 13(8), 1862.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Pecori R, et al. (2022) ADAR RNA editing on antisense RNAs results in apparent U-to-C base changes on overlapping sense transcripts. Frontiers in cell and developmental biology, 10, 1080626.

Biggi AFB, et al. (2022) The Epstein-Barr Virus Hacks Immune Checkpoints: Evidence and Consequences for Lymphoproliferative Disorders and Cancers. Biomolecules, 12(3).